Angiotensin Receptor Blockers in Aortic Stenosis
Key facts
- Where
- Québec, CanadaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 99 years old?
Source: NCT04913870, who can take part
Where in Canada
- CRIUCPQQuébec, CanadaContact: Marie-Annick Clavel, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
- Trial code
- NCT04913870EU 2024-518389-28-00
- Record updated
- 20 December 2024
- Original description
This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.Read full original descriptionShow less
Impact of Angiotensin Receptor Blockers in Aortic Stenosis - a Randomized Controlled Trial
This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.
Inclusion: Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and <4m/s); Normal left ventricular ejection fraction (i.e. ≥50%); Systolic blood pressure >110 mmHg; Diastolic blood pressure >70 mmHg.
Exclusion: Current use or documented indication for renin-angiotensin system medication or Aliskiren; Known allergy or intolerance to angiotensin II receptor blockers (ARBs); Alzheimer, dementia or known non-compliant patient; Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment; Newly diagnosed (<2 months) or poorly controlled diabetes; Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (<3 months); More than mild aortic or mitral regurgitation, or mitral stenosis; Renal dysfunction (glomerular filtration rate <30ml/min/1.73m2); Chronic hyperkalemia; Pregnant or lactating women; Patients unable to read, understand or sign research consent.